ELOVL6 rs7185374: Longevity and Mid-to-Late Life Survival
The genetic variant rs7185374 is a single nucleotide polymorphism linked to the ELOVL6 pathway and investigated in major studies of human aging. Research has associated specific alleles at this locus with reduced mid-to-late life mortality and increased odds of reaching exceptional longevity. While it provides intriguing insights into the biology of survival, it represents only a small statistical influence within the complex genetics of human lifespan.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| CC | Carriers of the homozygous CC genotype have two copies of the minor allele associated with reduced mid-to-late life mortality. In centenarian cohort studies, this genotype has been linked to lower rates of age-related cardiovascular events and higher odds of reaching extreme age. It reflects a modest statistical advantage in survival models rather than an absolute guarantee of longevity. | Favorable |
| AC | Individuals with the AC genotype carry one copy of the longevity-associated C allele and one copy of the ancestral A allele. They typically exhibit intermediate statistical odds of mid-to-late life survival compared to homozygous carriers in population research. Its impact is subtle and strongly modulated by broader lifestyle, environment, and polygenic background. | Informational |
| AA | The AA genotype is the most common combination observed in the general population across multiple ancestral cohorts. Carrying two common alleles confers the baseline population rate of age-related survival and vascular disease risk. It does not indicate an inherent health deficit, as typical lifestyle factors remain the dominant predictors of lifespan. | Informational |
Genetic Overview and Chromosomal Context
The single nucleotide polymorphism rs7185374 is a common human genetic variant mapped to the human genome and studied in relation to age-related survival. In longevity genetics, it is functionally evaluated in connection with lipid metabolic pathways, particularly alongside genes like ELOVL6 that govern fatty acid homeostasis. Centenarian and survival analyses, including investigations published in [The Journals of Gerontology: Series A](https://academic.oup.com/biomedgerontology/article/72/11/1453/3072309), examine variants like rs7185374 to understand how subtle genomic variations across chromosomes shape late-life survivorship. Like many non-coding variants identified in large-scale cohort studies, rs7185374 likely operates through regulatory mechanisms, such as modifying the expression of nearby regulatory elements or acting in linkage with functional metabolic loci. Cataloged in reference repositories such as [dbSNP](https://www.ncbi.nlm.nih.gov/snp/rs7185374), this locus exemplifies how non-coding genomic differences can correlate with downstream patterns of human healthspan.
Biological Role of Fatty Acid Elongation and ELOVL6
The metabolic context surrounding this locus frequently involves fatty acid elongation, a biological process driven by enzymes such as ELOVL fatty acid elongase 6 (ELOVL6), detailed at [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/79071). ELOVL6 catalyzes the elongation of saturated and monounsaturated fatty acids, converting palmitate into stearate, thereby dictating cellular lipid membrane composition and energy balance. Animal and human studies synthesized in [Life Sciences](https://www.sciencedirect.com/science/article/abs/pii/S0024320524008981) show that modulating ELOVL6 activity profoundly alters insulin sensitivity, hepatic lipid accumulation, and vascular health. Elevated palmitoleic acid levels—often seen when elongation pathways are altered—have repeatedly been correlated with metabolic resilience and longevity across model organisms and human centenarian cohorts. Because chronic metabolic dysfunction and atherosclerosis represent major drivers of middle- and late-life mortality, variations modulating lipid elongase networks present a biologically plausible pathway influencing human healthspan.
Research Findings on Longevity and Mortality
Evidence linking rs7185374 to survivorship stems primarily from genome-wide association studies across cohorts such as the New England Centenarian Study (NECS) and the Long Life Family Study (LLFS), available via [PubMed Central](https://pmc.ncbi.nlm.nih.gov/articles/PMC5861867/). Researchers discovered that the less common C allele (and homozygous CC genotype) demonstrated a statistical association with exceptional longevity. Crucially, longitudinal survival analyses revealed that this enrichment in centenarians was largely driven by decreased mortality during middle-to-late adulthood rather than an exclusive protective effect operating only at century-old ages. Participants harboring the favorable longevity alleles also exhibited lower risks for major cardiovascular diseases and hypertension. However, the evidence strength remains moderate: extreme longevity is profoundly polygenic, and variations at rs7185374 account for small individual effect sizes that interact with hundreds of other loci and lifestyle determinants.
Interpreting Results: What You Can and Cannot Do
Discovering your rs7185374 genotype offers educational insight into your genetic profile, but it is not a diagnostic test or an absolute forecast of your lifespan. A favorable genotype does not make an individual immune to chronic illness, nor does a neutral or less favorable genotype guarantee a shortened life. Longevity is heavily shaped by modifiable factors, including cardiovascular fitness, dietary composition, regular exercise, tobacco avoidance, and access to preventive medical screenings. Consumers should not alter prescription regimens, diet plans, or medical treatments based on this SNP alone. If you have questions about your personal cardiovascular risk, metabolic health, or family medical history, those inquiries should always be discussed directly with a qualified physician or genetic counselor.
How common is this variant?
The minor allele associated with altered survival demonstrates a minor allele frequency (MAF) of approximately 0.20 to 0.25 in populations of European ancestry, meaning the CC genotype is carried by a relatively small percentage of individuals in the general population.
Frequently asked questions
Does having the rs7185374 CC genotype mean I will live to 100?
No, carrying the CC genotype does not guarantee extreme longevity. Centenarian studies show that genetic variants like rs7185374 provide modest statistical increases in mid-to-late life survival, but lifestyle, environment, and numerous other genes play far larger roles.
What is the biological connection between ELOVL6 and aging?
ELOVL6 is an enzyme involved in the elongation of long-chain fatty acids, directly influencing cellular fat composition, insulin sensitivity, and vascular health. Maintaining favorable lipid elongation profiles helps protect against metabolic disorders and cardiovascular complications that commonly limit lifespan.
Can I take a supplement to mimic the effects of the longevity allele?
There are no approved supplements or over-the-counter medications that safely replicate this variant's genetic effects. Instead, adhering to established cardiovascular health habits—such as consuming an anti-inflammatory diet rich in unsaturated fats, exercising regularly, and managing blood pressure—remains the evidence-based approach to longevity.
Why is rs7185374 described as affecting mid-to-late life survival?
Survival modeling from aging cohorts indicates that carriers experience a reduced mortality hazard primarily between late middle age and elderly years, notably due to reduced rates of cardiovascular disease. Consequently, more carriers survive into their nineties and beyond, creating an enrichment of the allele among centenarians.
Sources & further reading
Educational information only, last refreshed 9/4/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7185374?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29